Research Advances on the Pathogenesis and Treatment of Hemolytic Uremic Syndrome --Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 636-640, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-928767
ABSTRACT
Hemolytic uremic syndrome (HUS) is clinically rare, with high mortality and case fatality rates. In recent years, the research on HUS has been intensified and the pathophysiological mechanism has been continuously improved. At present, the main mechanism of pathogenesis is the excessive activation of complement alternative pathways mediated by complement-related gene mutations or the existence of antibodies. The treatment methods and strategies are also constantly updated, mainly including complement-blocking drugs such as Eculizumab, Lavalizumab, and Ravulizumab. In this review, the new developments in the pathogenesis and treatment of HUS is summarized, and provide references for the clinical treatment of HUS.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Proteínas del Sistema Complemento
/
Síndrome Hemolítico-Urémico
/
Mutación
Tipo de estudio:
Estudio de etiología
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS